Translating inflammatory bowel disease research into clinical medicine

Markus F Neurath; Susetta Finotto

doi:10.1016/j.immuni.2009.08.016

Translating inflammatory bowel disease research into clinical medicine

Immunity. 2009 Sep 18;31(3):357-61. doi: 10.1016/j.immuni.2009.08.016.

Authors

Markus F Neurath¹, Susetta Finotto

Affiliation

¹ Department of Medicine, University of Erlangen-Nürnberg, 91054 Erlangen, Germany. markus.neurath@uk-erlangen.de

PMID: 19766078
DOI: 10.1016/j.immuni.2009.08.016

Abstract

Recent studies have provided important insights into the pathogenesis of inflammatory bowel disease (IBD). The development of new therapeutic agents has been triggered by basic research and studies in mouse models of IBD. It is expected that improved translational research will lead to optimized therapy and new individualized treatment options.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Inflammatory Agents / therapeutic use*
CD4-Positive T-Lymphocytes / immunology
Disease Models, Animal
Drug Discovery*
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / etiology
Inflammatory Bowel Diseases / immunology
Interleukins / immunology
Mononuclear Phagocyte System / immunology

Substances

Anti-Inflammatory Agents
Interleukins